Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00757887
Recruitment Status : Completed
First Posted : September 23, 2008
Last Update Posted : November 9, 2010
Information provided by:
Radboud University

September 22, 2008
September 23, 2008
November 9, 2010
October 2009
August 2010   (Final data collection date for primary outcome measure)
  • A significant difference in time of thick smear positivity between EHMI-8 and control volunteers [ Time Frame: 21 days ]
  • A significant quantitative difference in parasitemia as measured by PCR between EHMI-8 and control volunteers [ Time Frame: 21 days ]
  • A significant difference in kinetics of parasitemia between EHMI-8 and control volunteers as measured by PCR. [ Time Frame: 21 days ]
  • A difference in occurrence of signs or symptoms between EHMI-8 and control volunteers [ Time Frame: 21 days ]
Same as current
Complete list of historical versions of study NCT00757887 on Archive Site
Difference in immunological parameters between EHMI-8 and control volunteers. [ Time Frame: 140 days ]
Same as current
Not Provided
Not Provided
Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites
Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites
In the EHMI-8 study (CMO 2006/207) the investigators induced sterile protection against P. falciparum challenge in healthy Dutch volunteers by repeated exposure to infected mosquitoes whilst under chloroquine prophylaxis. The surprisingly efficient induction of protection in this study strongly supports the development of whole parasite vaccines and is therefore an important finding to malaria vaccine development. In this study (EHMI8B) the investigators would like to explore the longevity of the protective immune response and simultaneously further characterise immune mechanisms responsible for protection by re-exposing EHMI-8 volunteers to infected mosquito bites.
Not Provided
Not Applicable
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
P. Falciparum Malaria
Biological: Exposure to 5 P. falciparum infected mosquitoes
Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
  • Experimental: EHMI8
    Previously protected volunteers, N=10
    Intervention: Biological: Exposure to 5 P. falciparum infected mosquitoes
  • Active Comparator: control
    5 malaria-naive volunteers
    Intervention: Biological: Exposure to 5 P. falciparum infected mosquitoes
Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011 May 21;377(9779):1770-6. doi: 10.1016/S0140-6736(11)60360-7. Epub 2011 Apr 22.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
August 2010
August 2010   (Final data collection date for primary outcome measure)

Inclusion criteria

  1. Age > 18 and < 35 years healthy volunteers (males or females).
  2. General good health based on history and clinical examination.
  3. Negative pregnancy test.
  4. Use of adequate contraception for females
  5. All volunteers have to sign the informed consent form following proper understanding of the meaning and procedures of the study
  6. Volunteer agrees to inform the general practitioner and agrees to sign a request for medical information concerning contra-indications for participation in the study
  7. Willingness to undergo a P. falciparum sporozoite challenge
  8. Resident near the RUNMC, Nijmegen or agree to stay in a hotel room during the intensive period of the study (Day 5 till Day T +3)
  9. Reachable by mobile phone during the whole study period
  10. Availability to attend all study visits
  11. Agreement to refrain from blood donation to Sanquin or for other purposes, during the course of the study
  12. Willingness to undergo an HIV, hepatitis B and C test
  13. Negative urine toxicology screening test at screening visit and day before challenge

Exclusion criteria

  1. History of malaria other than participation in EHMI-8, or residence in malaria endemic areas within the past six months
  2. Plans to travel to endemic malaria areas during the study period.
  3. Only for newly recruited control volunteers: previous participation in any malaria vaccine study and/or positive serology for P. falciparum
  4. Symptoms, physical signs and laboratory values suggestive of systemic disorders, including renal, hepatic, cardiovascular, pulmonary, skin, immunodeficiency, psychiatric and other conditions, which could interfere with the interpretation of the study results or compromise the health of the volunteers.
  5. History of diabetes mellitus or cancer (except basal cell carcinoma of the skin)
  6. History of arrhythmia's or prolonged QT-interval
  7. Positive family history in 1st and 2nd degree relatives of cardiac disease < 50 years old
  8. An estimated, ten year risk of fatal cardiovascular disease of ≥5%, as estimated by the Systematic Coronary Risk Evaluation (SCORE) system.
  9. Any clinically significant deviation from the normal range in biochemistry or haematology blood tests or in urine analysis
  10. Positive HIV, HBV or HCV tests
  11. Participation in any other clinical study within 30 days prior to the onset of the study
  12. Volunteers enrolled in any other clinical study during the study period
  13. Pregnant or lactating women
  14. Volunteers unable to give written informed consent
  15. Volunteers unable to be closely followed for social, geographic or psychological reasons
  16. Previous history of drug or alcohol abuse interfering with normal social function during a period of one year prior to enrolment in the study
  17. A history of psychiatric disease
  18. Known hypersensitivity for anti-malaria drugs
  19. History of severe reactions or allergy to mosquito bites
  20. The use of chronic immunosuppressive drugs, antibiotics, or other immune modifying drugs within three months before study onset (inhaled and topical corticosteroids are allowed) and during the study period
  21. Contra-indications to Malarone® including treatment taken by the volunteers that interfere with Malarone®
  22. Any confirmed or suspected immunosuppressive or immunodeficiency condition, including asplenia
  23. Co-workers of the departments of Medical Microbiology or Internal Medicine of the Radboud University Nijmegen Medical Centre
Sexes Eligible for Study: All
18 Years to 35 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Prof. Dr. R.W. Sauerwein, Radboud University
Radboud University
Not Provided
Principal Investigator: Robert Sauerwein, Prof. Dr. Radboud University
Radboud University
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP